• Explore /
  • Poster
  • / Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.

Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.

Abstract Poster

Authors

Philippe Merle

Philippe Merle

Croix-Rousse Hospital, Hepatology Unit, Lyon, France;

Philippe Merle , Mohamed Bouattour , Jean-Frédéric Blanc , Jean-Marie Peron , Marilyne Debette-Gratien , Pierre Nahon , Jean Marc Phelip , Eric Assenat , Vincent Bourgeois , Carine Richou , Alexandra Heurgue , Jean-Pierre Bronowicki , Isabelle Ollivier-Hourmand , Thomas Uguen , Stéphane Cattan , Sylvie Thevenon , Camille Boucheny , Pierre Pradat , Eric Nguyen-Khac

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03963206

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 573)

DOI

10.1200/JCO.2023.41.4_suppl.573

Abstract #

573

Poster Bd #

E5

Abstract Disclosures

Similar Posters

First Author: Mathias Earl Palmer

First Author: Robin Kate Kelley

First Author: Robin Kate Kelley

First Author: Ghassan K. Abou-Alfa